Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Infections

Respiratory Tract (Lung and Bronchial) Diseases

Symptoms and General Pathology

Prostatic Neoplasms

COVID-19

Pneumonia

Pneumonia, Viral

Communicable Diseases

Respiratory Tract Infections

Virus Diseases

Coronavirus Infections

Coronaviridae Infections

Nidovirales Infections

RNA Virus Infections

Lung Diseases

Respiratory Tract Diseases

We will measure the PSA value during and after Covid-19 infection in the same group via paired simple t test

We measure PSA value during and after covid-19 infection

PSA value

Omer G Doluoglu, Associate Professor

Omer G Doluoglu

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a worldwide pandemic in over 100 years. The disease caused by this newly discovered virus was called Covid-19. In this study, we aimed to evaluate changing of PSA value in patients with Covid-19.

Patients with positive PCR test results were included in the study. The age of the patient and urea, leukocyte, hemoglobin, platelet, urea, and creatinine values of the patients were recorded. Urinalysis and urine culture were taken from all patients. Acute phase reactants such as sedimentation, C-reaktif protein (CRP), ferritin, and fibrinogen were measured both at the time the patients applied and three weeks after the patient recovered. PSA and free PSA were also measured in the same way. Patients whose symptoms improved and the PCR test result was negative were considered as recovered.

We measured PSA value during and after Covid-19 infection

The male patients \>45 and \<70 years of age included to the study

Changing of Prostate Specific Antigen Value in Patients With Covid-19

Changing of PSA With Covid-19

Saglik Bilimleri Universitesi

Ankara Training and Research Hospital

Recurrence

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Patients with prostate cancer and confirmed biochemical recurrence with PSA of ≥ 0.2 ng/ml after radical prostatectomy or PSA \> nadir + 2ng/ml after radiotherapy but not radio-morphological local recurrence after primary therapy with curative intent will receive systemic therapy with \[177Lu\]Lu-PSMAI\&T radioligand therapy

2 cycles (3 GBq in first cycle and 6 GBq in the second cycle) of \[177Lu\]Lu-PSMAI\&T radioligand therapy at 6-week intervals

[177Lu]Lu-PSMA I&T

Sazan Rasul, PhD

Shahrokh F. Shariat, Professor

Pawel Rajwa, MD

Prospective single-center one-arm phase II study in patients with prostate cancer and confirmed biochemical recurrence (BCR) with PSA of ≥ 0.2 ng/ml after radical prostatectomy (RP) or PSA \> nadir + 2ng/ml after radiotherapy (RT) but not radio-morphological local recurrence after primary therapy with curative intent receive systemic therapy with only 2 cycles of highly standardized (3 GBq in first cycle and 6 GBq in the second cycle) PSMA-RLT at 6-week intervals.

Prospective single-center one-arm phase II study

PSMA-RLT in Biochemically Recurrent PCa

[177Lu]Lu-PSMAI&T Radioligand Therapy (PSMA-RLT) for Patients With Prostate Cancer and Biochemical But Not Radio-morphological Local Recurrence After Primary Therapy With Curative Intent: A Prospective Phase II Pilot Study

in term of PSA decline of ≥ 50% from baseline value

in terms of pathological (Grade 3) reduction of values of blood count (hemoglobin decreased \<8.0 g/dL; \<4.9 mmol/L; \<80 g/L; platelet count decreased \<50,000 - 25,000/mm3; \<50.0 - 25.0 x 10e9 /L and white blood cell decreased \<2000 - 1000/mm3; \<2.0 - 1.0 x 10e9 /L. ), kidney (creatinine increased \> 3.0 x baseline or \>3.0 - 6.0 x upper limit of normal (UNL)) and liver functions (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and GGT increased \>5.0 - 20.0 x ULN if baseline was normal or \>5.0 - 20.0 x baseline if baseline was abnormal; albumin \<2 g/dL or \<20 g/L; bilirubin increased \>3.0 - 10.0 x ULN if baseline was normal or \>3.0 - 10.0 x baseline if baseline was abnormal and lactate dehydrogenase increased \> ULN.), assessed by Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.

analyze the time until the start of androgen deprivation therapy

Using the questionnaires: FACT-P, EORTC QLQ

In terms of appearance of new PSMA-avid lesions and/or size progression of the metastatic lymph nodes evaluated based on response evaluation criteria of solid tumor (RECIST) version 1.1.

Quantification of circulating free tumor DNA (ctDNA), enumeration of circulating tumor cells (CTCs) before and following \[177Lu\]Lu-PSMAI\&T-RLT and analyse molecular changes in liquid biopsy markers following \[177Lu\]Lu-PSMAI\&T-RLT.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Changing of Prostate Specific Antigen Value in Patients With Covid-19	NCT05009186	Covid19 Prostate Specif...	PSA value	45 Years - 70 Years	Saglik Bilimleri Universitesi
Changing of Prostate Specific Antigen Value in Patients With Covid-19	NCT05009186	Covid19 Prostate Specif...	PSA value	45 Years - 70 Years	Saglik Bilimleri Universitesi
PSMA-RLT in Biochemically Recurrent PCa	NCT06220188	Prostate Cancer...	[177Lu]Lu-PSMA ...	18 Years - 80 Years	Medical University of Vienna

Spots Global Cancer Trial Database for psa value

Every month we try and update this database with for psa value cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for psa value

Every month we try and update this database with for psa value cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for psa value cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.